InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.25%
)
US TECH 100
19,426.00
(
0.54%
)
Dow Jones
42,208.22
(
0.20%
)
Brent Oil
74.39
(
-0.23%
)
Bitcoin
64,438.28
(
0.26%
)
Post# of 253213
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120491
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 210805

Saturday, 04/22/2017 7:49:21 PM

Saturday, April 22, 2017 7:49:21 PM

Post# of 253213

Is NASH going to end up similar to…HCV market? Looks very crowded.

Yes and yes:

• NASH will end up having a couple of winners (maybe three) and many losers.

• The NASH winners will have combination regimens (#msg-129038646).

• NASH will become a large market provided that imaging biomarkers are validated as prognostic (#msg-130518050).

A drug from the FXR-agonist class (#msg-128917063) will likely be one constituents of successful NASH regimens.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up